BackVicore Pharma Holding AB Overview
Vicore Pharma Holding AB

Vicore Pharma Holding AB PEG Ratio

Valuation check: VCRE's PEG ratio is 5.79, below the Healthcare sector average of 12.15.

Get informed when a big investor buys or sells

+ Follow

PEG Ratio

5.79

PEG Ratio

5.79

The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.

PEG Ratio (Comparison Companies)

Loading

PEG Ratio History

Loading

PEG Ratio Comparison

Loading

Vicore Pharma Holding AB (VCRE) FAQ

Vicore Pharma Holding AB's peg ratio stands at 5.79. That is below the Healthcare sector average of 12.15. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Vicore Pharma Holding AB sits lower the Healthcare benchmark (12.15) with a PEG ratio of 5.79. That is roughly 52.3% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 5.79 is attractive depends on Vicore Pharma Holding AB's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Vicore Pharma Holding AB's PEG ratio evolved across reporting periods, while the comparison chart places VCRE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, PEG ratio is commonly used to spot outliers. Vicore Pharma Holding AB's reading of 5.79 (sector avg 12.15) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.